Invesco NASDAQ Biotech UCITS ETF | SBIO

Register to Unlock Ratings
Performance History31/10/2024
Growth of 1,000 (GBP) Advanced Graph
Invesco NASDAQ Biotech UCITS ETF
          | 
          SBIO
Fund23.40.4-0.80.25.1
+/-Cat-2.59.57.11.43.7
+/-B’mrk-9.50.1-3.2-7.2-0.7
 
Key Stats
Closing Price
22/11/2024
 USD 46.93
Day Change 2.60%
Morningstar Category™ Sector Equity Biotechnology
Volume 38610
Exchange LONDON STOCK EXCHANGE, THE
ISIN IE00BQ70R696
Fund Size (Mil)
21/11/2024
 USD 306.98
Share Class Size (Mil)
21/11/2024
 USD 306.98
Ongoing Charge
16/02/2024
  0.40%
Investment Objective: Invesco NASDAQ Biotech UCITS ETF | SBIO
The investment objective of the Fund is to achieve the total return performance of the NASDAQ Biotechnology Index (the "Reference Index") less fees, expenses and transaction costs. The Reference Index is designed to represent the performance of biotechnology and pharmaceutical securities on the NASDAQ Stock Market®.
Returns
Trailing Returns (GBP)22/11/2024
YTD4.80
3 Years Annualised0.43
5 Years Annualised5.60
10 Years Annualised6.45
12 Month Yield 0.00
Management
Manager Name
Start Date
-
-
Inception Date
06/11/2014
Advertisement
Category Benchmark
Fund BenchmarkMorningstar Benchmark
NASDAQ Biotechnology TR USDMorningstar Gbl Biotechnology NR USD
Target Market
Role In Portfolio
Standalone / CoreNot Specific
ComponentNot Specific
OtherNot Specific
Primary Objective
PreservationNot Specific
GrowthYes
IncomeNot Specific
HedgingNot Specific
OtherNot Specific
Portfolio Profile for  Invesco NASDAQ Biotech UCITS ETF | SBIO31/10/2024
Morningstar Style Box®
Equity Style
Asset Allocation
  % Long% Short% Net Assets
Stock100.000.00100.00
Bond0.000.000.00
Property0.000.000.00
Cash0.000.000.00
Other0.000.000.00
Top 5 Regions%
United States87.85
United Kingdom5.78
Eurozone3.42
Europe - ex Euro1.25
Asia - Emerging1.07
Top 5 Sectors%
Healthcare100.00
Top 5 HoldingsSector%
TRS NASDAQ Biotechnology TR USD100.00
Invesco NASDAQ Biotech UCITS ETF | SBIO

Related

In order to provide consistency across the report data provided by different Asset Managers, the calculated data points presented are generated using Morningstar’s proprietary calculation methodology which is set out in more detail at(https://www.morningstar.com/research/signature)
© Copyright 2024 Morningstar, Inc. All rights reserved.

Terms of Use        Privacy Policy        Modern Slavery Statement        Cookie Settings        Disclosures